The average one-year price target for Werewolf Therapeutics (NasdaqGS:HOWL) has been revised to $5.30 / share. This is a ...

Werewolf Therapeutics, Inc. (HOWL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...

Fintel reports that on May 12, 2023, B of A Securities maintained coverage of Werewolf Therapeutics (NASDAQ:HOWL) with a Buy recommendation. As of May 11, 2023, the average one-year price target for ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

Director Luke Evnin reported selling shares of Werewolf Therapeutics Inc (NASDAQ:HOWL) between December 2nd and December 4th, 2025. The sales, executed under a prearranged 10b5-1 trading plan, totaled ...